Objective: Total parenteral nutrition (TPN), with the complete removal of enteral nutrition, results in marked changes in intestinal intraepithelial lymphocyte (IEL) function and phenotype. Previous work shows that TPN results in a loss of intestinal epithelial cell-derived interleukin-7 (IL-7), and this loss may play an important role in development of such TPN-associated IEL changes. Methods: To further understand this relation, we generated a transgenic mouse (IL-7 vill ), which overexpresses IL-7 specifically in intestinal epithelial cells. We hypothesized that this localized overexpression would attenuate many of the observed TPN-associated IEL changes. Results: Our study showed that TPN administration led to significant changes in IEL phenotype, including a marked decline in the CD8␣␤ϩ, CD4ϩ, and ␣␤-TCRϩ populations. IEL basal proliferation decreased 1.7-fold compared with wild-type TPN mice. TPN administration in wild-type mice resulted in several changes in IEL-derived cytokine expression. IL-7 vill mice given TPN, however, maintained IEL proliferation, and sustained normal IEL numbers and phenotype. Conclusions: We conclude that specific intestinal IL-7 overexpression significantly attenuated many IEL changes in phenotype and function after TPN administration. These findings suggest a mechanism by which TPN results in observed IEL changes. (Ann Surg 2008;248: 849 -856) From the †Departments
T otal parenteral nutrition (TPN) is vital for patients unable to take enteral feedings. However, TPN is associated with several major complications that include the loss of immune reactivity and an increase in infectious complications and generalized septicemia. [1] [2] [3] [4] Although the underlying mechanism for this is unknown, it may be that a loss of TPNassociated intestinal immune functionality leads to bacterial translocation and subsequent sepsis. 5, 6 Our previous studies have also shown that TPN administration resulted in marked changes in intestinal intraepithelial lymphocyte (IEL) phenotype and function, and these changes may have an important role in how administration of TPN is associated with a loss of immune function. 5, 7 Although it is unknown what mechanism(s) lead to these TPN-associated IEL changes, deraignment of mucosal immune function has also been observed by other investigators. 8, 9 IELs is a distinct population of T lymphocytes, which are located at the basolateral side of epithelial cells (EC) in the epithelial layer of the intestine. This cell population, although not fully defined, seems to play a critical role in modulation of mucosal immune responses and in the control of epithelial cell growth and function. 10, 11 Studies from our laboratory have found that TPN administration results in a marked decline in intestinal EC-derived interleukin-7 (IL-7) expression. 7, 12, 13 Recently, our laboratory has shown that systemic IL-7 administration into healthy wildtype mice significantly altered IEL phenotype and function, including an increase in ␣␤-T-cell receptor (TCR)ϩ, CD8␣␤ϩ IELs, and the formation of a mature (CD44ϩ) IEL population. 14 Additionally, systemic IL-7 resulted in significant changes in IEL-derived cytokine expression. Furthermore, we also showed a close physical cross-communication between EC-derived IL-7 and IELs. 15, 16 Finally, our laboratory and other researchers have shown that systemic administration of IL-7 may prevent some of the observed TPNassociated changes in the mucosal immune system. 16, 17 IL-7 has been found to be essential for homeostatic proliferation of naive peripheral T cells. 18 IL-7 is produced by both thymic and intestinal EC, 19 -21 and in turn, IL-7 receptors (IL-7R) have been detected on the surface of thymocytes and IELs. 16, 20 Recently, a study from our group found that IL-7R was identified on CD4ϩ, CD8␣␣ϩ, and the CD8␣␤ϩ IEL subtypes. IL-7R were also identified in both ␣␤-TCRϩ IEL and ␥␦-TCRϩ IEL subpopulations. 16 Several studies have indicated that EC may play an important role in mucosal immune responses by helping to regulate neighboring IELs. 16, 22 It has been shown that IL-7 knock-out and IL-7 receptor knock-out mice show distinct declines in absolute numbers of thymocytes and IELs; and for the latter, a reduc-tion in ␣␤-TCRϩ IELs and a complete absence of ␥␦-TCRϩ IELs have been noted. 23 A major problem with previous studies examining IL-7 function is that the cytokine has either been delivered by systemic administration, 16, 17 systemic IL-7 overexpression, or conversely, the systemic blockade of the IL-7/IL-7R pathway (using anti-IL-7R antibody). 15, 24 Such studies may result in a confounding of the systemic versus local actions of IL-7 on the mucosal immune system. Unfortunately, this prevents one from gaining a detailed analysis of how the EC and IEL populations might be modulated by local IL-7 production. In the single study that examined the local expression of IL-7, Laky et al created a restitution of IL-7 EC expression in IL-7 knock-out mice, and demonstrated that this was sufficient to regain development of ␣␤-TCRϩ IEL and ␥␦-TCRϩ IEL populations. 25 To better understand the role that intestinal EC-derived IL-7 has in directing IEL lineage and function, we established an intestinal EC-specific overexpressing IL-7 transgenic mouse model. We hypothesized the specific overexpression of IL-7 by intestinal EC would attenuate the effect of TPN on the IEL.
METHODS

Animals
Studies reported here conformed to the guidelines for the care and use of laboratory animals established by the University Committee on Use and Care of Animals at the University of Michigan, and protocols were approved by that committee. Mice were maintained in temperature, humidity, and light-controlled conditions. During administration of intravenous solutions, mice were housed in metabolic cages.
Creation of IL-7 Transgenic Mice Development of a P12.4KVill-IL-7 Transgene
We used a previously characterized 12.4 Kb murine villin promoter/enhancer fragment to drive the expression of an IL-7 cDNA exclusively in the epithelium of the large and small intestine. 26 The full-length sequence of mouse IL-7 cDNA (generously donated by Dr. Jay Bream, NIH/NIAMS) was cloned behind the 12.4 Kb villin promoter/enhancer. The final clone used for transgenesis (P12.4KVILL-IL-7) was confirmed by restriction digestion and sequence analysis (across the complete IL-7 and into the villin sequences).
Generation of IL-7 vill Transgenic Mice
The transgene, containing villin-regulatory sequences linked to IL-7, was prepared by digestion of P12.4KVILL-IL-7 with PmeI. After purification, transgene DNA was injected into the pronuclei of fertilized ova (C57BL/6J ϫ SJL/J) by the University of Michigan Transgenic Animal Core. Six founders were identified by PCR amplification of tail DNA with primers specific for the transgene (Forward primer: ACAGGCACTAAGGGAGCCAATG; Reverse primer: TCCTGTCAT TTTGTC CAATTCA). Founders were then mated to C57BL/6J mice for the creation of F1 hybrids. Transgenic lines were maintained by crossing transgenic mice with C57BL/6J mice; transgenic animals were identified by PCR analysis of their tail DNA.
Total Parenteral Nutrition Model
Administration and composition of TPN was performed as described previously. 5 IL-7 vill and wild-type (C57BL/6J) were infused with a crystalloid solution (dextrose 5% in 0.45 normal saline with 20 mEq KCl/L) at 4 mL/d. After 24 hours, mice were randomized into 4 groups (n ϭ 6 each group). Control Groups: Wild-type and IL-7 vill mice received the same intravenous crystalloid solution at 7 mL/24 hours, in addition to standard laboratory mouse chow and water ad libitum. TPN Groups: Wildtype and IL-7 vill TPN mice received an intravenous TPN solution at 7 mL/24 hours. The TPN solution contained a balanced mixture of amino acids, lipids, and dextrose in addition to electrolytes, trace elements, and vitamins. 5 Caloric delivery was similar in each group, as based on estimates of caloric intake measurements in the control group and from previous investigators. 5 All animals were sacrificed at 7 days using CO 2 .
IEL Isolation and Purification IEL Isolation From Small Intestine
Small bowel IELs and EC were isolated using a Percoll gradient as described previously. 5 After mucosal cell isolation, supernatants contained an enriched IEL population and EC. In some cases, the IEL was further purified by filtering through a glass wool column, and by using magnetic beads conjugated with antibody to CD3 (BioMag SelectaPure Anti-Mouse Antibody Particles, Polyscience Inc, Warrington, PA). Cells bound to beads were considered purified IELs; remaining EC were in the supernatant. Flow cytometry confirmed purity of sorted cells, which was greater than 99%.
Reverse Transcriptase Polymerase Chain Reaction Isolation of Total Ribonucleic Acid
A guanidinium isothiocyanate-chloroform extraction method was used. Total ribonucleic acid (RNA) from isolated EC or IELs was extracted using Trizol reagent (Life Technologies, Inc., MD) according to the manufacturer's directions.
Reverse Transcriptase (RT) and Polymerase Chain Reaction (PCR)
Poly-A tailed mRNA was reversed transcribed into complementary DNA by adding total cellular RNA to the following reaction mixture: PCR Nucleotide Mix (Invitrogen, CA), M-MLV Reverse Transcriptase (Invitrogen), Oligo(dT) [12] [13] [14] [15] [16] [17] [18] Primer (Invitrogen), and RNAse Inhibitor (40 U/L, Roche Diagnostics, Germany). Diethyl pyrocarbonatetreated H 2 O was added to yield the appropriate final concentration. For quantification of the IL-7 mRNA (including transgenic IL-7 mRNA) expression study, IL-7 primers were designed by using sequence from the encodable sequence of mouse IL-7cDNA. Forward primer: TGCCCGAATAAT-GAACCAA, right primer: CAACCTCTCCAAGTTATGAA-CCAGTAG. 16 For transgenic IL-7 gene detection, we used a unique primer set that stretched across a portion of the villin promoter and IL-7 sequence; the forward primer was designed from Exon-1: CAACTTCCTAAGATCTCCCAG-GTG, the reverse primer was designed from IL-7 cDNA: GTTCCTGTCATTTTGTCCAATTC. The PCR products were run out on a 2% agarose gel. Quantification of cDNA product was completed using a Kodak 1D image quantification software (Kodak Co, NY), and target PCR products were compared by normalizing each sample to the production of ␤-actin.
Immunoblot Analysis for EC-Derived IL-7 Expression
Briefly, isolated EC was homogenized on ice in lysis buffer. 27 Protein determination was performed by using a Micro BCA Protein Assay Kit (PIERCE, Rockford, IL). Approximately 40 g of total protein in loading buffer was loaded per lane in a SDS-polyacrylamide-gel (13%), and separated using electrophoresis. Proteins were then transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories, CA). The membrane was blocked with blocking solution (Zymed Laboratories Inc, CA), and probed with goat antimouse biotinylated-IL-7 antibody (R&D Systems, Inc., MN) (0.15 g/mL in blocking solution) for 1 hour. Bound antibodies were exposed to a streptavidin-HRP conjugate (1:10000, Zymed Laboratories Inc, CA), detected on x-ray film. Blots were then stripped and reprobed with monoclonal mouse anti ␤-actin antibody (1:8000 in blocking solution; Sigma, St Louis, MO) to confirm equal loading of protein.
The peroxidase-conjugated second antibody was goat antimouse IgG (1:8000 in blocking solution; Invitrogen). Quantification of results was performed using Kodak 1D image quantification software (Kodak Co, NY). Thus, results of immunoblots are expressed as the relative expression of IL-7 to beta actin expression.
Flow Cytometric Analysis IEL Phenotype Analysis
IEL phenotype was studied using fluorescent-labeled antibody staining detected with flow cytometry. Monoclonal antibodies (BD PharMingen, San Diego, CA) consisted of anti-CD4, CD8␣, CD8␤, ␣␤-TCR, ␥␦-TCR; CD44 and CD69 antibodies were used to examine phenotype expression of IEL subsets. Flow cytometry was performed using standard techniques. 28 Acquisition and analysis were performed on a FACSCalibur (Becton-Dickinson, Mountain View, CA) using CellQuest software (Becton-Dickinson). The IEL population was gated based on forward and side scatter characteristics. Quantification of each subpopulation was based on its percentage of the gated IEL population.
IEL Cell Cycle Analysis
The modified protocol of Geiselhart et al 19 was used. Briefly, separated IELs were labeled with FITC-CD3. Surfaced-labeled or unlabeled IELs were permeabilized by resuspension in saponin buffer (0.1% BSA, 0.01 M HEPES, 0.1% saponin in PBS) at a concentration of 0.5 ϫ 10 6 cells/mL for 10 minutes, followed by centrifugation at 1500 rpm for 5 minutes at 4°C. The supernatant was decanted and the pellet was resuspended in a saponin buffer containing 200 g/mL of propidium iodide (Sigma Aldrich, St. Louis, MO) and 50 g/mL of RNase (Roche Diagnostics Corporation, Indianapolis, IN) followed by incubation for 15 minutes at 4°C. Labeled cells were analyzed by using a FACSCalibur flow cytometer and CellQuest (Becton-Dickinson) software for cell cycle analysis.
Data Analysis
Data are expressed as mean Ϯ SD. Results were analyzed using ANOVA, and a Bonferroni post hoc analysis was used to detect differences between groups. Statistical significance was defined as P Ͻ 0.05.
RESULTS
General Descriptions of Specific Intestinal EC Overexpression of IL-7 in IL-7 vill Mice
It has been shown that IL-7 is produced by intestinal EC and plays an important role in mucosal immune responses by regulation of growth and function of IELs. 20 More recently, a study from our laboratory showed that TPN results in a loss of intestinal (EC)-derived IL-7, and this may play an important role in TPN-associated IEL changes. 16 To further address this, we generated a transgenic mouse (IL-7 vill ), using a 12.4 kb villin promoter fragment drives IL-7 cDNA specific expression in intestinal EC from the pylorus, throughout the small bowel, and colon. 26 Six initial founders were identified by Genotype PCR analysis and bred on a background of C57Bl/6 mice.
Intestinal EC-derived IL-7 mRNA expression was significantly higher in transgenic mice than wild-type mice (3-fold increase compared with wild-type by PCR). Western blot analysis showed significantly increased EC-derived IL-7 expression when compared with wild-type mice (P Ͻ 0.05; Fig. 1 ). Thus, EC-derived IL-7 expression increased nearly 3-fold when compared with wild-type mice. This correlated with the significant increase in IEL numbers, and significantly altered phenotype, maturation, and function of the IEL.
Changes in IEL Number
TPN administration led to a significant decrease in IEL numbers when compared with controls. Numbers of IELs significantly decreased (by 35%) after TPN administration. IEL numbers in IL-7 vill mice, however, were significantly higher compared with wild-type mice. IEL numbers in transgenic mice increased 3-fold when compared with wild-type mice. When IL-7 vill mice were given TPN, IEL numbers were much higher than wild-type mice who were receiving TPN, and numbers of IELs were similar to enterally fed mice (P Ͻ 0.05; Fig. 2 ). This represents a 2-fold increase in the number of harvested IELs in IL-7 vill TPN mice compared with wildtype TPN mice.
Changes in IEL Phenotype
Several changes were identified in IEL surface phenotypic markers with TPN administration. Both the CD4ϩ, CD8Ϫ and CD4ϩ, CD8ϩ IEL subpopulations decreased significantly compared with controls; CD4ϩ, CD8Ϫ IELs decreased 87% and CD4ϩ, CD8ϩ IELs decreased 80%, respectively. In contrast, IL-7 vill mice have much larger CD4ϩ, CD8Ϫ and CD4ϩ, CD8ϩ IEL subtype populations; CD4ϩ, CD8-IELs were increased 5-fold, and CD4ϩ, CD8ϩ IELs increased 3.1-fold, respectively compared with wild-type mice. IL-7 vill mice given TPN had higher levels of CD4ϩ, CD8Ϫ and CD4ϩ, CD8ϩ IEL subpopulations compared with wild-type TPN mice (P Ͻ 0.05; Fig. 3 ). The levels of these populations were not significantly different from wild-type control mice.
Loss of the CD8␣␤ϩ IELs was also observed after TPN administration. The percentage of CD8␣␤ϩIELs decreased nearly 6-fold when compared with wild-type control mice (P Ͻ 0.05). In contrast, IL-7 vill mice have a much larger population of CD8␣␤ϩIELs. The CD8␣␤ϩIEL population increased 5.6-fold when compared with wild-type mice. Additionally, IL-7 transgenic mice receiving TPN have a much higher CD8␣␤ϩ population compared with wild-type TPN mice (P Ͻ 0.05; Fig. 4 ).
TCR subpopulations were also studied. The ␣␤-TCRϩ IELs decreased after TPN administration; this represented a decline from 33% of all gated IELs to 22% after TPN administration. The relative percentage of ␣␤-TCR ϩ IELs was found to be significantly higher in IL-7 vill mice when compared with wild-type mice (Fig. 5) , representing a 2.4fold increase compared with wild-type mice. Further, IL-7 transgenic mice showed a much higher percent of ␣␤-TCR ϩ IEL subtype with TPN administration compared with wildtype TPN mice (P Ͻ 0.05; Fig. 5 ).
Changes in IEL Maturation and Activation
CD44 was used as a marker of lymphocyte maturation, whereby maturity is manifested by increased expression. The CD44ϩ IEL subset declined in the TPN group compared with control animals (Fig. 6 ). The CD8ϩ, CD44ϩ subset in the TPN group showed a 65% decline (P Ͻ 0.05), and the CD4ϩ, CD44ϩ subset showed a 55% decline with TPN administration ( Fig. 6 ; P Ͻ 0.05). In contrast, IL-7 vill mice have higher CD4ϩ, CD44ϩ and CD8ϩ, CD44ϩ IEL populations compared with wild-type control mice, with an increase by 4.7-fold and 1.4 fold over wild-type mice for the CD4 ϩ , CD44ϩ and CD8 ϩ , CD44ϩ IEL subtypes, respectively. IL-7 transgenic mice with TPN administration have much higher CD4ϩ, CD44ϩ and CD8ϩ, CD44ϩ subpopulations compared with wild-type TPN mice (P Ͻ 0.05; Fig.  6 ), such that there was no significant difference between this group and the control, enterally fed wild-type group. The presence of CD69 was used as a marker of activated T-cells, 29 with higher expression of CD69 seen in more activated T-cells. The CD4ϩ, CD69ϩ IEL subpopulation was found to be significantly (P Ͻ 0.05) lower after TPN administration, and was noted to be significantly increased in IL-7 vill mice compared with wild-type mice (P Ͻ 0.05; Fig.  7 ). The CD4ϩ, CD69ϩ IEL subtype increased nearly 6-fold in IL-7 vill mice compared with wild-type mice. This level of CD4 ϩ , CD69ϩ IELs in TPN transgenics was much higher than wild-type TPN mice, and statistically (P Ͻ 0.05) similar to wild-type enterally fed control mice (Fig. 7 ).
IEL Functionality Changes in IEL Proliferation
Because of the profound effect of TPN on IEL phenotypic changes and decline in IEL numbers, IEL proliferation rates were studied. TPN administration resulted in a decrease in IEL proliferation; with rates declining 1.7-fold compared with control mice (P Ͻ 0.05; Fig. 8 ). IL-7 transgenic mice have higher IEL proliferation levels compared with wild-type mice, and IL-7 transgenic mice receiving TPN have higher proliferation levels compared with wild-type TPN mice (P Ͻ 0.05; Fig. 8 ). IEL proliferation levels increased 82% in IL-7 vill mice with TPN administration when compared with wild-type TPN mice, such that these levels of proliferation were not significantly different from the wild-type enterally fed group.
Changes in IEL Cytokines Expression
A panel of cytokines was selected to represent the activities responsible for both T-cell activation and those that could contribute to a down-regulation of T-cell activity. 30 Results are shown in Figure 9 . IEL cytokine expressions were significantly altered after TPN administration. IL-10 expression declined, whereas IFN-␥, TNF-␣ showed a significant increase in expression (109% and 30%, respectively; both P Ͻ Annals of Surgery • Volume 248, Number 5, November 2008 Intestinal Specific Overexpression of IL-7 0.05 compared with controls), when compared with the control group. IEL-derived IL-10 expression decreased 58% after TPN administration. The remaining cytokines that were examined, including IL-2, IL-4, and IL-6, showed little to no change after TPN administration. Transgenic IL-7 vill mice expressed higher levels of IL-10, IFN-␥, and TNF-␣, but not IL-2, IL-4, and IL-6. IL-7 vill mice with TPN administration retained significantly higher IL-10 expression level compared with wild-type TPN mice (P Ͻ 0.05); however, other cyto-kines, including IL-2, IL-6, and TNF-␣, showed no significant difference between wild-type TPN group and IL-7 vill TPN group.
DISCUSSION
In this study, we found that intestinal EC-specific overexpression of IL-7 using IL-7 vill mice resulted in a significant expansion of the IEL population and affected IEL phenotype and function. IEL functional changes included a significant increase in IEL proliferation and alterations in IEL cytokine expressions. IL-7 vill mice given TPN manifested significantly fewer of the TPN-associated IEL alternations compared with wild-type mice given TPN. Of these differences, IL-7 vill TPN mice had sustained populations of CD4ϩ and ␣␤-TCRϩ IEL compared with wild-type TPN mice, and the percent of these populations was similar to the IEL subpopulation levels of wild-type control mice. IL-7 vill mice receiving TPN also had a much higher CD8␣␤ϩ IEL subpopulation than wild-type TPN mice. Additionally, IL-7 vill mice undergoing TPN administration had much higher levels of IEL proliferation level compared with wild-type TPN mice.
Interactions between IEL and intestinal EC are thought to be crucial for maintaining intestinal mucosal immunity. Previous studies by our group have shown that IEL play an important role in the maintenance of the gut barrier function and in the support of intestinal EC growth. 6, 7, 11, 13, 31 Several studies have indicated that EC may have an important role in mucosal immune responses by helping to regulate IEL phenotype and function. 20, 22 EC has been shown to act as antigen presenting cells for both CD4ϩ and CD8ϩ IEL. 32, 33 It has also been shown that EC are known to produce a number of immunologically important cytokines, including IL-6, 34 IL-7, and IL-10. 20, 35 Of these cytokines, the IL-7/IL-7R-dependent signaling pathway has been shown to play a crucial role in regulating the immune response in the intestinal mucosa. 20,24,36 -38 Receptors for IL-7 have been identified on CD4ϩ, CD8␣␣ϩ, and CD8␣␤ϩ IEL phenotype, and also ␣␤-TCRϩ and ␥␦-TCRϩIEL subpopulations. 16 Recently, a study from our laboratory showed that IL-7R blockade with anti-IL-7R antibody resulted in several phenotypic IEL changes that were quite similar to those observed in TPN mice. 15 These changes include a loss of the CD8␣␤, CD4ϩ, CD44ϩ, and CD4ϩ (including the CD4ϩ, CD8ϩ, and CD4ϩ, CD8Ϫ) IEL subpopulations. Additionally, IL-7R blockade reduced the total number of IEL. 15 Similarly, other groups have reported that IL-7 knock-out and IL-7R knock-out mice show distinct declines in absolute numbers of thymocytes and IEL. 23 Kenai et al 39 found that anti-IL-7 antibody treatment disturbed the induction of ␣␤-TCRϩ T-cells after athymic nude mice were implanted with fetal thymocytes. In our present study, intestinal EC-specific overexpression of IL-7 resulted in a significant increase in the total number of IEL, significant changes in IEL phenotype, and increases in the level of IEL proliferation. It seems that this increase in IEL numbers was, at least in part, because of an IL-7-induced increase in IEL proliferation. Similar to our findings, a recent article by Fukatsu et al 17 noted the importance of IL-7 in immune alterations because of TPN. These authors noted that the exogenous FIGURE 8. IEL proliferation. IEL were surface-labeled with fluorochrome-conjugated antibody to CD3, and then treated with propidium iodide for detection of cell cycle status using flow cytometric analysis. TPN administration significantly decreased IEL proliferation when compared with controls, P Ͻ 0.05. IL-7 transgenic mice receiving TPN have much higher proliferation levels compared with wild-type TPN mice; *P Ͻ 0.05 compared with the TPN group.
FIGURE 9.
Changes in IEL-derived cytokine mRNA expression. TPN administration significantly changed IEL cytokine expression. IEL-derived IL-10, IFN-␥, and TNF-␣ expressions were significantly changed after TPN administration. Transgenic IL-7 mice maintained high levels of IL-10 compared with wild-type TPN mice; however, IL-7 vill mice continued to express IFN-␥ and TNF-␣ at levels similar to that of wild-type TPN mice. No significant changes were seen in IL-2, IL-4, and IL-6. Values (mean Ϯ SD) are expressed as the ratio of target cytokine versus expression of ␤-actin; *P Ͻ 0.05 compared with the TPN group.
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Annals of Surgery • Volume 248, Number 5, November 2008 administration of IL-7 reversed GALT-associated changes; however, IL-7 was unable to restore diminished levels of immunoglobulin A. Administration of TPN led to a significant decrease in the CD4ϩ, CD8 Ϫ ; CD4ϩ, CD8ϩ; and CD8ϩ, CD44ϩ IEL subpopulations, 5 and a loss of CD8␣␤ϩ IEL. 40 In this current study, we further confirmed these IEL phenotype changes after TPN administration. The precise etiology of these changes after TPN administration remains uncertain. A previous investigation by our laboratory found that IL-7 administration prevented the development of the majority of TPNassociated IEL phenotype changes and the decline in total IEL numbers. 16 Furthermore, IL-7 administration in wildtype mice also led to a significant increase in the percent of CD8␣␤ϩ IEL, and significantly increased the absolute numbers of IEL. 15 The importance of EC-derived IL-7 is also underscored by a previous study of ours that showed that there is a close physical connection between EC-derived IL-7 and the neighboring IEL. 15 These studies suggest that cellto-cell interactions between EC and IELs, via IL-7, could be an important model of communication for the maintenance and activation of the IEL. Previous attempts at trying to understand the relevance of IL-7 in this TPN model by using exogenous administration of IL-7 have many disadvantages. In particular, this approach will lead to a broad number of IL-7-mediated systemic actions. [41] [42] [43] One particular disadvantage to systemic overexpression of IL-7 has been the formation of colitis 24 -a potential major obstacle to the utilization of systemic IL-7 for clinical applications. Although not formally studied in our transgenic mice, we have not observed colitis with the confined expression that predominates in the small intestine. These findings may confound the relevance of locally expressed EC-derived IL-7. Similar confounding results could well occur in a previous model, in which IL-7 overexpression is driven by an SR␣ promoter, whereby IL-7 expression is seen in a wide array of systemic tissues. 24 To further investigate the role EC-derived IL-7 has in directing IEL lineage and function, we established an intestinal EC specific overexpressing IL-7 transgenic mouse model. We found that the IEL population in these transgenic mice was significantly expanded; consisting of an increase in the CD4ϩ, CD8␣␤ϩ, and␣␤-TCRϩ IEL subtypes. The increase in IEL subtypes is disproportionately biased toward an expansion (compared with wild-type mice) of the CD4ϩ IEL population; CD4ϩ IEL increased 9-fold, compared with CD8ϩ IEL that increased 4-fold. A greater expansion of the ␣␤-TCRϩ IEL compared with the ␥␦-TCRϩ IEL subpopulation was also noted. These observations seem consistent with the fact that IL-7R is detected to a much higher level on CD4ϩ and ␣␤-TCRϩ IEL compared with the CD8 and ␥␦-TCRϩ IEL subpopulations. 16 IL-7 has been shown to enhance peripheral T-cell expression of IL-4 mRNA and IL-4 production. 44, 45 Jiang and McGee 46 found that EC-derived IL-7 could enhance human peripheral T-cell IL-4 secretion, but not IFN-␥ in a cell culture model. 46 A recent study from our group showed that exogenous IL-7 administration to wild-type health mice can up-regulate IEL-derived IL-2 and IL-10 expression; however, IL-7 had no effect on the expression of IL-4 or IL-6. 15 In our present study, we found that IL-7 vill mice expressed higher levels of IL-10, IFN-␥, TNF-␣; however, we could not find any significant change in IL-2, IL-4, and IL-6 expression between IL-7 vill mice and wild-type mice. The reason for this discrepancy is not entirely clear, but may be due to differential action of IL-7 between peripheral T-cells and the IEL. Thus, it is possible that exogenous administration of IL-7 may stimulate extramucosal lymphoid populations, and that these extramucosal population changes may account for the observed increase in IEL-derived IL-2 that was not found in our transgenic mouse model. A decline in mucosally derived IL-10 has been observed with TPN administration by other investigators. 9 The finding of a decline in IL-10 after TPN administration may have significant physiologic relevance in that this cytokine may greatly influence epithelial barrier function. 47, 48 Future studies on our IL-7 vill mice will need to be done to examine how the sustained expression of IL-10 during TPN administration may affect intestinal barrier function. It is important to note that our IL-7 transgenic mice failed to reverse the observed rise in both IFN-␥ and TNF-␣ that was noted in our TPN wild-type group. This suggests that other mechanisms aside from IL-7 must account for some of the TPN-associated cytokine changes that occur in the IEL, and further studies will need to address the mechanisms that drive these latter changes. TPN administration can impair the ability to fight systemic infections and this is due to a number of derangements in the local gut associated lymphoid tissue. 49, 50 Future studies will also be needed to better understand if the sustained expression of IL-7 with TPN in our transgenic mice can prevent this increase in infections.
In conclusion, this study demonstrated that intestinal EC-specific overexpression of IL-7 significantly affected IEL phenotype and function, and also resulting in an increased IEL numbers. Such IL-7 vill mice failed to manifest many of the TPN-associated alternations seen in the IEL of wild-type mice. The results of this study suggest that EC-derived IL-7 contribute to several of the alternations observed in the IEL population after TPN. This study also further confirms the close physical and functional cross-communication between EC-derived IL-7 and mucosal IEL.
